We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
-$417M
Cap. Flow
-$178M
Cap. Flow %
-6.89%
Top 10 Hldgs %
30.75%
Holding
151
New
30
Increased
31
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$42M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$38M
3
AAC
AAC Holdings
AAC
+$37.8M
4
GSK icon
GSK
GSK
+$37.7M
5
RGNX icon
Regenxbio
RGNX
+$34.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$132M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$38M
3
INGN icon
Inogen
INGN
+$26.8M
4
AERI
Aerie Pharmaceuticals
AERI
+$25.4M
5
BSX icon
Boston Scientific
BSX
+$24.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.89%
2 Financials 4.77%
3 Technology 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADYX
76
DELISTED
Adynxx Inc
ADYX
$5.32M 0.21%
27,959
-26
-0.1% -$7.28K
STRM
77
DELISTED
Streamline Health Solutions
STRM
$5.21M 0.2%
151,517
+30,000
+25% +$1.21M
ATXS
78
DELISTED
Astria Therapeutics
ATXS
$5.08M 0.2%
10,475
-1,826
-15% -$1.3M
SCYX icon
79
SCYNEXIS
SCYX
$42.4M
$5.04M 0.2%
8,660
– –
TCON
80
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$4.74M 0.18%
2,425
– –
ATYR
81
aTyr Pharma
ATYR
$50M
$4.74M 0.18%
32,966
– –
DSCI
82
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$4.72M 0.18%
1,002,201
+33,320
+3% +$215K
STDY
83
DELISTED
SteadyMed Ltd
STDY
$4.67M 0.18%
1,315,169
+47,592
+4% +$217K
AKRX
84
DELISTED
Akorn Inc
AKRX
$4.58M 0.18%
160,667
-184,000
-53% -$7.6M
ALDX icon
85
Aldeyra Therapeutics
ALDX
$102M
$4.03M 0.16%
690,538
– –
PEN icon
86
Penumbra
PEN
$12.5B
$4.01M 0.16%
+100,000
New +$4.04M
CASM
87
DELISTED
CAS Medical Systems, Inc.
CASM
$4M 0.15%
3,200,000
– –
BDSI
88
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.89M 0.15%
+700,000
New +$5.17M
MRTX
89
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.79M 0.15%
110,049
-287,611
-72% -$8.69M
EYPT icon
90
EyePoint Inc
EYPT
$1.12B
$3.55M 0.14%
97,211
+86,929
+845% +$3.41M
GNCA
91
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.43M 0.13%
62,657
-7,875
-11% -$781K
ARAV
92
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.19M 0.12%
+46,167
New +$4.33M
PRQR icon
93
ProQR Therapeutics
PRQR
$240M
$3.05M 0.12%
209,398
– –
CDTX
94
DELISTED
Cidara Therapeutics
CDTX
$3.02M 0.12%
11,879
– –
BITI
95
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$2.87M 0.11%
219,558
– –
IVTY
96
DELISTED
Invuity, Inc
IVTY
$2.82M 0.11%
201,068
-17,455
-8% -$229K
TRIB
97
Trinity Biotech
TRIB
$6.79M
$2.81M 0.11%
49,200
-3,298
-6% -$265K
BEAT
98
DELISTED
BioTelemetry, Inc.
BEAT
$2.72M 0.11%
222,215
-422,085
-66% -$5.38M
WINT
99
DELISTED
Windtree Therapeutics Inc
WINT
$2.56M 0.1%
609,857
+348,450
+133% +$2.31M
MZOR
100
DELISTED
Mazor Robotics Ltd.
MZOR
$2.52M 0.1%
228,909
-32,091
-12% -$414K
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2015 Portfolio in Review

As of Q3 2015, Deerfield Management held 151 positions worth $2.59B, down 14% from $3B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Deerfield Management withdrew a net $178M in Q3 2015, closing 17 positions and reducing 32 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Global Blood Therapeutics, Inc. worth $37.5M.

  • Deerfield Management's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 890,620 shares worth $37.5M.
  • Deerfield Management added most to AAC Holdings in Q3 2015, an estimated $37.8M increase.
  • Deerfield Management's biggest Q3 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $132M.
  • Deerfield Management fully exited Spark Therapeutics, Inc. Common Stock in Q3 2015, selling an estimated $38M.
  • Deerfield Management's ten largest holdings make up 31% of its $2.59B portfolio in Q3 2015.
  • Deerfield Management opened 30 new positions and closed 17 in Q3 2015.
  • Deerfield Management's portfolio value fell 14% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q3 2015, filed 16 Nov 2015.